ViiV HEALTHCARE ANNOUNCES CHMP POSITIVE OPINION FOR TRIUMEQ PD, THE FIRST DISPERSIBLE SINGLE TABLET REGIMEN CONTAINING DOLUTEGRAVIR, A ONCE-DAILY TREATMENT FOR CHILDREN LIVING WITH HIV IN EUROPE

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Triumeq PD, a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine for the treatment of paediatric patients weighing 14kg to <25 kg with human immunodeficiency virus type 1 (HIV-1). The CHMP’s positive opinion includes the label extension of Triumeq tablet, lowering the minimum weight that a child with HIV-1 can be prescribed this medicine from 40kg to 25kg.

Additional information to the following link: https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2022/december/viiv-healthcare-announces-chmp-positive-opinion-for-triumeq-pd/